Pfizer Expands Xalkori Labeling To New, Rare Lung Cancer Subtype
This article was originally published in The Pink Sheet Daily
New indication now allows use in non-small cell lung cancer patients with rare ROS-1 genetic alterations.
You may also be interested in...
Alectinib will launch within two weeks for second-line ALK-positive non-small lung cancer at the price of $12,500 per month.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.